Preventing Anal Cancer: Results from the ANCHOR Study
Joel M. Palefsky, MD, FRCP (C)
Professor of Medicine, Division of Infectious Diseases
University of California, San Francisco, CA
Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc. Copyright © 2022. All rights reserved.
Joel Palefsky, M.D., C.M., F.R.C.P.(C). Professor of Medicine and Infectious Diseases at the University of California San Francisco School of Medicine. He is an internationally recognized expert on the molecular biology, treatment, pathogenesis and natural history of anogenital human papillomavirus infections, particularly in the setting of HIV infection. He is the director of the world's first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic Research and Education Center at the UCSF Cancer Center. He is the vice-chair of the National Cancer Institute (NCI)-supported AIDS Malignancy Consortium. He is the chair of the Anal Cancer /HSIL Outcomes Research (ANCHOR) Study, a national multi-site NIH study designed to determine whether treatment of anal cancer precursor lesions prevents the development of anal cancer and to identify biomarkers of progression. He is founder and past president of the International
Anal Neoplasia Society and is past president of the International Papillomavirus Society.
At the completion of this educational session, participants will:
1. Understand the rationale for and design of the ANCHOR Study
2. Know the results of the ANCHOR Study
3. Be able to discuss the implications of the ANCHOR Study
Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.
- Dr. James F. Braun, DO (Course Director) has no relevant financial relationships to disclose.
- Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose.
- Dr. Joel M. Palefsky (Presenter) has had the following personal financial relationships in the past 24 months with manufacturers of the products or services that may be presented in this CME activity: Scientific Advisory Board Member, Grant Recipient, and Speaker at Merck; Consultant to Vir Biotechnologies, Antiva Biosciences, and Viron Therapeutics (w/Viron stock options.) Dr. Palefsky submitted their slides in advance for adequate peer review, and will support their presentation and clinical recommendations with the best available evidence from the medical literature. All relevant financial relationships have been mitigated.
This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare
Download Article PDF/Slides